Eli Lilly

Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Bloomberg
Pfizer
M&A
Bristol-Myers Squibb
Celgene
Eli Lilly
AstraZeneca
Flag link:
Payer Power: Why Eli Lilly, Janssen, and Merck Deeply Discount Their Drug Prices
Payer Power: Why Eli Lilly, Janssen, and Merck Deeply Discount Their Drug Prices
Drug Channels
Eli Lilly
Janssen
Merck
drug pricing
drug discounts
Flag link:
Pharma turns to new pain options amid opioid crisis
Pharma turns to new pain options amid opioid crisis
Biopharma Dive
opioids
opioid crisis
painkillers
payers
Eli Lilly
abuse deterrents
Flag link:
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Drug Delivery Business News
Eli Lilly
Sigilon
cell therapies
drug development
type 1 diabetes
Flag link:
Lilly's Cyramza succeeds in late-stage liver cancer trial
Lilly's Cyramza succeeds in late-stage liver cancer trial
Yahoo/Reuters
Eli Lilly
Cyramza
liver cancer
clinical trials
Flag link:
Tired of finishing in last place, Eli Lilly’s new R&D chief wants to shake things up
Tired of finishing in last place, Eli Lilly’s new R&D chief wants to shake things up
Endpoints
Eli Lilly
R&D
Dan Skovronsky
Flag link:
Half-off sale at Eli Lilly as drug rebating climbs to 51% in 2017
Half-off sale at Eli Lilly as drug rebating climbs to 51% in 2017
Fierce Pharma
Eli Lilly
drug rebates
drug pricing
diabetes
Flag link:
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Fierce Pharma
AbbVie
Eli Lilly
Amgen
executive pay
drug pricing
Flag link:
Lilly's bet on pain stands out amid bare pharma pipeline
Lilly's bet on pain stands out amid bare pharma pipeline
Biopharma Dive
Eli Lilly
painkillers
galcanezumab
tanezumab
Lasmiditan
Flag link:
CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business
CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business
Morningstar
CVS
Eli Lilly
PBMs
Flag link:
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Endpoints
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib
Flag link:
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Flag link:
Migraine maven Lilly finds 'understanding gap' between patients, nonpatients in new survey
Migraine maven Lilly finds 'understanding gap' between patients, nonpatients in new survey
Fierce Pharma
migraines
Eli Lilly
patients
Flag link:
Large and Small: Here’s What’s Moving Eli Lilly and Zosano
Large and Small: Here’s What’s Moving Eli Lilly and Zosano
Yahoo/Market Exclusive
Eli Lilly
Zosano
Verzenio
advanced breast cancer
M207
migraine
Flag link:
Lilly touts Ph3 data for once-weekly Type II diabetes medication
Lilly touts Ph3 data for once-weekly Type II diabetes medication
Drug Delivery Business News
Eli Lilly
diabetes
clinical trials
Trulicity
Flag link:
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
Flag link:
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
Flag link:
$690M deal in peril after Lilly ends mid-stage studies
$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Flag link:
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Endpoints
Eli Lilly
rheumatoid arthritis
Hanmi Pharmaceutical
clinical trials
Flag link:
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Xconomy
Eli Lilly
Taltz
Flag link:

Pages